%PDF-1.3
%ºß¬à
3 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 4 0 R
>>
endobj
4 0 obj
<<
/Length 4973
>>
stream
0.200025 w
0 G
BT
/F2 24 Tf
27.5999999999999979 TL
0 g
200.7999999999999829 769.8899999999999864 Td
(Susac Syndrome) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 719.8899999999999864 Td
(# Susac Syndrome: A Comprehensive Review of Epidemiology, Clinical Manifestations,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 703.8899999999999864 Td
(Pathophysiology, and Treatment Options) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 671.8899999999999864 Td
(**Keywords:** susac; syndrome:; comprehensive; introduction; epidemiology; clinical;) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 655.8899999999999864 Td
(pathophysiology) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 623.8899999999999864 Td
(**Citation Style:** APA) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 591.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 559.8899999999999864 Td
(## Abstract) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 527.8899999999999864 Td
(Susac syndrome is a rare and complex autoimmune disorder characterized by a clinical triad) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 511.8899999999999864 Td
(of central nervous system dysfunction, branch retinal artery occlusions, and sensorineural) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 495.8899999999999864 Td
(hearing impairment. The epidemiology and demographics of Susac syndrome are crucial) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 479.8899999999999864 Td
(aspects of understanding this disease, with a variable geographical distribution, age and sex) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 463.8899999999999864 Td
(distribution, and clinical presentation. The clinical manifestations of Susac syndrome are) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 447.8899999999999864 Td
(diverse, including neurological, audio-vestibular, and ophthalmological symptoms, and the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 431.8899999999999864 Td
(diagnosis can be challenging due to its heterogeneous presentations and potential for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 415.8899999999999864 Td
(relapse and long-term sequelae. The pathophysiology of Susac syndrome involves) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 399.8899999999999864 Td
(immune-mediated endotheliopathy, which affects the microvasculature of the brain, retina,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 383.8899999999999864 Td
(and inner ear. Treatment options for Susac syndrome are limited, and effective management) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 367.8899999999999864 Td
(strategies are crucial to prevent long-term visual and hearing impairments. This review aims) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 351.8899999999999864 Td
(to provide a comprehensive overview of the current knowledge on Susac syndrome,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 335.8899999999999864 Td
(highlighting the key findings from recent studies on its epidemiology, clinical manifestations,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 319.8899999999999864 Td
(pathophysiology, and treatment options.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 287.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 255.8899999999999864 Td
(## 1. Introduction) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 223.8899999999999864 Td
(Susac syndrome is a rare autoimmune disorder that was first described in 1979 by John) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 207.8899999999999864 Td
(Susac and his colleagues. The disease is characterized by a clinical triad of central nervous) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 191.8899999999999864 Td
(system dysfunction, branch retinal artery occlusions, and sensorineural hearing impairment.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 175.8899999999999864 Td
(Despite its rarity, Susac syndrome is an important condition that can have significant) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 159.8899999999999864 Td
(implications for patients' quality of life. The epidemiology and demographics of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 143.8899999999999864 Td
(syndrome are not well understood, and the disease is often misdiagnosed or) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 127.8899999999999864 Td
(underdiagnosed. The clinical manifestations of Susac syndrome are diverse, and the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 111.8899999999999864 Td
(diagnosis can be challenging due to its heterogeneous presentations and potential for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 95.8899999999999864 Td
(relapse and long-term sequelae. Recent studies have shed light on the pathophysiology of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 79.8899999999999864 Td
(Susac syndrome, which involves immune-mediated endotheliopathy, and have highlighted) Tj
ET
endstream
endobj
5 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 6 0 R
>>
endobj
6 0 obj
<<
/Length 5517
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(the importance of early diagnosis and treatment to prevent long-term complications. This) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(review aims to provide a comprehensive overview of the current knowledge on Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(syndrome, highlighting the key findings from recent studies on its epidemiology, clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(manifestations, pathophysiology, and treatment options.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(## Introduction to Susac Syndrome) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(No relevant research found for this section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(## Epidemiology and Demographics) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(### Epidemiology and Demographics) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(The epidemiology and demographics of Susac syndrome are crucial aspects of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(understanding this rare and complex disease. Susac syndrome is characterized by a clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(triad of central nervous system \(CNS\) dysfunction, branch retinal artery occlusions, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(sensorineural hearing impairment. Despite its rarity, studying the epidemiological and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(demographic characteristics of Susac syndrome can provide valuable insights into its) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(pathogenesis, diagnosis, and management. This section aims to summarize the current) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(knowledge on the epidemiology and demographics of Susac syndrome, highlighting the key) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(findings from recent studies.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(The following table summarizes the numerical data from the studies discussed in this section:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(| Study [n] | Sample Size | Key Metrics/Outcomes | Statistical Significance |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(| --- | --- | --- | --- |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(| [1] | 6 | Prevalence of Susac syndrome: 0.014-0.024 per 100,000, Mean age at) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(presentation: 36 years, Age range: 17-54 years, Proportion of patients with characteristic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(snowball lesions on MRI: 66%, Proportion of patients with retinal artery abnormalities: 50%,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(Proportion of patients with sensorineural hearing loss: 66%, Proportion of patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
( f a v o r a b l e   o u t c o m e   \( m R S  "d   2 \) :   8 6 %   |   -   |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(| [3] | 10 | Minimum five-year period prevalence: 0.148/100,000, Annual incidence:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(0.024/100,000, Minimum point prevalence rates: 0.030-0.088/100,000, Patients with typical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(callosal or internal capsule MRI lesions: 8/10, Patients with BRAO: 7/10, Patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(hearing loss or tinnitus: 5/10, Patients who developed the complete clinical triad: 4/10 | 95%) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(Confidence Interval for five-year period prevalence: 0.071-0.272, 95% Confidence Interval for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(annual incidence: 0.010-0.047, 95% Confidence Interval for minimum point prevalence rate) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(\(lower\): 0.004-0.108, 95% Confidence Interval for minimum point prevalence rate \(upper\):) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(0.032-0.192 |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(| [4] | 304 | Number of reported cases: 304 | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(The quantitative findings from these studies provide valuable insights into the epidemiology) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(and demographics of Susac syndrome. Study [1] reported a mean age at presentation of 36) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(years, with an age range of 17-54 years, and a proportion of patients with characteristic) Tj
ET
endstream
endobj
7 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 8 0 R
>>
endobj
8 0 obj
<<
/Length 6170
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(snowball lesions on MRI of 66% [1]. In contrast, study [3] reported a minimum five-year) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(period prevalence of 0.148/100,000 and an annual incidence of 0.024/100,000 [3]. Study [4]) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(compiled a comprehensive review of 304 reported cases, providing a reliable basis for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(understanding the demographic, clinical, and diagnostic characteristics of the disease [4].) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(### Age and Sex Distribution) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(The age and sex distribution of Susac syndrome patients is an important aspect of its) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(demographics. Study [1] reported an equal distribution of males and females \(3:3\) among the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(six patients diagnosed with Susac syndrome [1]. In contrast, study [4] found that Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(syndrome affects predominantly young adults, with a female preponderance [4]. The median) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(age of onset was reported to be 28 years, with a median duration of symptoms before) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(diagnosis of 6 months [4]. These findings suggest that Susac syndrome may have a slightly) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(higher incidence in females, particularly in young adults.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(### Geographical Distribution and Prevalence) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(The geographical distribution and prevalence of Susac syndrome are also important aspects) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(of its epidemiology. Study [1] reported on the characteristics and management of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(syndrome in an emergent country, Brazil, highlighting the challenges faced by emergent) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(countries in diagnosing and managing the disease [1]. Study [3] provided the first) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(population-based data on the prevalence and incidence of Susac's syndrome in a Central) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(European population, reporting a minimum five-year period prevalence of 0.148/100,000 and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(an annual incidence of 0.024/100,000 [3]. These findings suggest that Susac syndrome is a) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(rare disease with a variable geographical distribution, and its prevalence may differ) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(significantly between different regions.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(### Clinical Characteristics and Outcomes) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(The clinical characteristics and outcomes of Susac syndrome patients are critical aspects of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(its epidemiology and demographics. Study [1] reported that the most common initial) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(symptoms were confusion, visual impairment, and hearing loss, and that characteristic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
("snowball" lesions on MRI were present in 66% of patients [1]. Study [4] found that the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(clinical triad of CNS dysfunction, branch retinal artery occlusions, and sensorineural hearing) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(impairment was present in the majority of cases, with 75% of patients presenting with CNS) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(symptoms, 70% with branch retinal artery occlusions, and 60% with sensorineural hearing) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(loss [4]. These findings suggest that Susac syndrome is a complex disease with a variable) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(clinical presentation, and its outcomes may depend on early diagnosis and treatment.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(In conclusion, the epidemiology and demographics of Susac syndrome are complex and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(multifaceted, with a variable geographical distribution, age and sex distribution, and clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(presentation. The quantitative findings from recent studies provide valuable insights into the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(prevalence, incidence, and clinical characteristics of Susac syndrome, highlighting the need) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(for increased awareness and recognition of this rare but important disorder. Further studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(are necessary to better understand the pathogenesis, diagnosis, and management of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(syndrome, and to improve patient outcomes.) Tj
ET
endstream
endobj
9 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 10 0 R
>>
endobj
10 0 obj
<<
/Length 6411
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(## Clinical Manifestations and Diagnostic Criteria) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(### Clinical Manifestations and Diagnostic Criteria) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(Susac syndrome is a rare and complex disease characterized by a range of clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(manifestations, including neurological, audio-vestibular, and ophthalmological symptoms.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(The diagnosis of Susac syndrome can be challenging due to its heterogeneous presentations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(and potential for relapse and long-term sequelae. A comprehensive understanding of the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(clinical manifestations and diagnostic criteria is essential for timely diagnosis and effective) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(management of the disease. This section provides an overview of the clinical characteristics) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(and diagnostic criteria of Susac syndrome, based on the analysis of several studies [5], [6],) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
([7], [8], and [9].) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(The following table summarizes the key metrics and outcomes from the studies:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(| Study [n] | Sample Size | Key Metrics/Outcomes | Statistical Significance |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(| --- | --- | --- | --- |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(| [5] | 435 | Percentage of males: 32.6%, Median age at diagnosis: 35 years, Frequency of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(neurological symptoms: 87.4%, Frequency of audio-vestibular symptoms: 84.3%, Frequency) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(of hearing loss: 87.9%, Frequency of BRAOs: 91.6%, Frequency of ophthalmological) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(symptoms: 78.9%, Frequency of complete triad at onset: 20.1%, Complete recovery rate in) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(neurological involvement: 59.5%, Complete recovery rate in ophthalmological symptoms:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(39.7%, Complete recovery rate in audio-vestibular symptoms: 17.7%, Partial recovery rate in) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(neurological involvement: 36.5%, Partial recovery rate in ophthalmological symptoms: 50.0%,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(Partial recovery rate in audio-vestibular symptoms: 38.7%, Median follow-up duration: 12) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(months, Rate of stable disease: 82.1%, Rate of relapse: 12.2%, Mortality rate: 5.7%, OS at 1) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(year: 94% \(95% CI 88-97%\), PFS at 1 year: 89% \(95% CI 80-94%\), PFS at 3 years: 83%) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(\(95% CI 69-91%\) | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(| [6] | - | Prevalence of nervous system involvement in BD patients: 10% | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(| [7] | 20 | Mean age at onset: 38.9 years, Mean follow-up: 55.9 months, Female-to-male) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(ratio: 1.86, Percentage of patients with complete clinical triad: 45%, Percentage of patients) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(with cognitive function improvement: 75%, Percentage of patients with hearing loss excluding) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(low frequencies at onset: 46.7%, Percentage of patients who resumed employment: 50%,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(Percentage of patients who did not return to work: 25% | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(| [8] | 21 | Patients with audiovestibular complaints: 21 \(100%\), Patients with predominant) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(low- to midfrequency sensorineural hearing loss: 15, Patients with abnormalities on vestibular) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(testing: 8/18 \(44.4%\) | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(The quantitative findings from the studies provide valuable insights into the clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(characteristics of Susac syndrome. Study [5] reported a high frequency of neurological) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(symptoms \(87.4%\), audio-vestibular symptoms \(84.3%\), and ophthalmological symptoms) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(\(78.9%\) in patients with Susac syndrome. The study also found that branch retinal artery) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(occlusions \(BRAOs\) were present in 91.6% of patients, and the complete triad of symptoms) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(was observed in only 20.1% of cases. In contrast, study [7] reported a lower frequency of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(complete clinical triad \(45%\) in their patient population. Study [8] found that all patients) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(\(100%\) presented with audiovestibular complaints, and 15 patients had predominant low- to) Tj
ET
endstream
endobj
11 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 12 0 R
>>
endobj
12 0 obj
<<
/Length 5774
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(midfrequency sensorineural hearing loss.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(### Neurological Manifestations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(The neurological manifestations of Susac syndrome are diverse and can include) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(encephalopathy, cognitive impairment, and psychiatric symptoms. Study [5] reported that) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(87.4% of patients presented with neurological symptoms, and 59.5% of patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(neurological involvement achieved complete recovery. In contrast, study [7] found that severe) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(cerebral involvement at onset was associated with a higher risk of cerebral exacerbations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(and increased long-term disability and dependency. Study [6] discussed the challenges of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(differential diagnosis in neuro-Behçet, a condition that can present with similar neurological) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(manifestations to Susac syndrome.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(### Audio-Vestibular Manifestations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(The audio-vestibular manifestations of Susac syndrome are also significant and can include) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(hearing loss, tinnitus, and vertigo. Study [8] found that all patients presented with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(audiovestibular complaints, and 15 patients had predominant low- to midfrequency) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(sensorineural hearing loss. Study [9] reported a case of unilateral hemi-central retinal artery) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(occlusion as a presenting sign of Susac syndrome, highlighting the importance of recognizing) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(rare presentations of the disease. Study [5] reported that 84.3% of patients presented with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(audio-vestibular symptoms, and 17.7% of patients with audio-vestibular symptoms achieved) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(complete recovery.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(### Ophthalmological Manifestations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(The ophthalmological manifestations of Susac syndrome can include BRAOs, retinal) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(arteriolar occlusions, and visual loss. Study [5] reported that 91.6% of patients presented with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(BRAOs, and 78.9% of patients presented with ophthalmological symptoms. Study [9]) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(reported a case of unilateral hemi-central retinal artery occlusion as a presenting sign of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(Susac syndrome, highlighting the importance of recognizing rare presentations of the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(disease. Study [7] found that cognitive function improved in 75% of patients during follow-up,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(but the study did not provide specific data on ophthalmological outcomes.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(In conclusion, the clinical manifestations and diagnostic criteria of Susac syndrome are) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(complex and diverse. The studies [5], [6], [7], [8], and [9] provide valuable insights into the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(clinical characteristics of the disease, including neurological, audio-vestibular, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(ophthalmological manifestations. Early recognition and treatment of Susac syndrome are) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(crucial to stabilize or decrease disease activity and potentially improve patient outcomes.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(Further research is necessary to improve our understanding of the disease and to develop) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(effective treatment strategies.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(## Pathophysiology and Disease Mechanisms) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(### Pathophysiology and Disease Mechanisms) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(The pathophysiology and disease mechanisms of Susac syndrome are complex and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(multifaceted, involving immune-mediated endotheliopathy, which affects the microvasculature) Tj
ET
endstream
endobj
13 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 14 0 R
>>
endobj
14 0 obj
<<
/Length 5884
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(of the brain, retina, and inner ear. Understanding the underlying mechanisms is crucial for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(the development of effective diagnostic and therapeutic strategies. This section aims to) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(provide a comprehensive overview of the current knowledge on the pathophysiology and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(disease mechanisms of Susac syndrome, highlighting key findings from recent studies.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(The following summary table provides an overview of the numerical data from the studies:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(| Study [n] | Sample Size | Key Metrics/Outcomes with values | Statistical Significance |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(| --- | --- | --- | --- |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(| [10] | - | Estimated diagnosed cases worldwide: 450 | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(| [11] | 21 | Patients with audiovestibular complaints: 100%, Patients with objectified) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(predominant low- to midfrequency sensorineural hearing loss: 71.4%, Patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(abnormalities on vestibular testing: 44.4% | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(The quantitative findings from these studies provide valuable insights into the disease) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(mechanisms of Susac syndrome. For example, study [11] found that 71.4% of patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(Susac syndrome had objectified predominant low- to midfrequency sensorineural hearing) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(loss, and 44.4% had abnormalities on vestibular testing. These findings suggest that) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(audiovestibular dysfunction is a common feature of Susac syndrome, and that early) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(recognition and treatment of these symptoms are crucial to prevent long-term sequelae.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(Study [10] provides a comprehensive review of the clinical presentation, diagnostic criteria,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(and potential pathophysiological mechanisms of Susac syndrome. The authors argue that) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(Susac syndrome can be classified as a delayed-type hypersensitivity autoimmune disorder,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(with potential triggers including genetic predisposition and previous immune challenges. This) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(study highlights the importance of early recognition and diagnosis of Susac syndrome to) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(prevent long-term neurological and sensory sequelae.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(In contrast, study [11] focuses on the vestibulocochlear manifestations of Susac syndrome,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(and found that vertigo and instability were the most frequently reported symptoms, followed) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(by hearing loss, tinnitus, and aural fullness. The authors suggest that aggressive) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(immunosuppression may prevent severe audiovestibular dysfunction, and that early) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(recognition and treatment of Susac syndrome are crucial to stabilize or decrease disease) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(activity.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(Study [12] provides a brief review of the literature on the neurocognitive and neuropsychiatric) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(manifestations of Susac syndrome, and highlights the significant neurocognitive and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(neuropsychiatric morbidity associated with this condition. The authors emphasize the need) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(for better phenotyping, understanding of pathophysiology, and evaluation of treatments on) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(cognitive and psychiatric outcomes.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(### Immune-Mediated Endotheliopathy) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(The immune-mediated endotheliopathy of Susac syndrome is a key feature of the disease,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(and is thought to be triggered by an autoimmune response to the endothelium of the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(microvasculature. Study [10] suggests that Susac syndrome can be classified as a) Tj
ET
endstream
endobj
15 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 16 0 R
>>
endobj
16 0 obj
<<
/Length 5714
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(delayed-type hypersensitivity autoimmune disorder, with potential triggers including genetic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(predisposition and previous immune challenges. This is supported by study [11], which found) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(that extensive immunosuppressive therapy may contribute to the mostly mild hearing loss) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(observed in patients with Susac syndrome.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(### Audiovestibular Dysfunction) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(Audiovestibular dysfunction is a common feature of Susac syndrome, and is thought to be) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(related to the immune-mediated endotheliopathy of the inner ear. Study [11] found that) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(71.4% of patients with Susac syndrome had objectified predominant low- to midfrequency) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(sensorineural hearing loss, and 44.4% had abnormalities on vestibular testing. These) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(findings suggest that early recognition and treatment of audiovestibular symptoms are crucial) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(to prevent long-term sequelae.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(### Neurocognitive and Neuropsychiatric Manifestations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(The neurocognitive and neuropsychiatric manifestations of Susac syndrome are significant,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(and are thought to be related to the immune-mediated endotheliopathy of the brain. Study) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
([12] highlights the need for better phenotyping, understanding of pathophysiology, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(evaluation of treatments on cognitive and psychiatric outcomes. The authors emphasize the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(importance of comprehensive neuropsychiatric assessment and management in patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(Susac syndrome.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(In conclusion, the pathophysiology and disease mechanisms of Susac syndrome are) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(complex and multifaceted, involving immune-mediated endotheliopathy, audiovestibular) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(dysfunction, and neurocognitive and neuropsychiatric manifestations. Further research is) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(needed to fully understand the underlying mechanisms of this condition, and to develop) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(effective diagnostic and therapeutic strategies. Readers are encouraged to view the full-text) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(versions of the cited studies for further information and visual evidence, such as microscopy) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(images and audiological testing results.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(## Treatment Options and Management Strategies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(### Treatment Options and Management Strategies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(The management of Susac syndrome, a rare autoimmune disorder affecting the eyes, brain,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(and ears, poses significant challenges due to its complex clinical presentation and limited) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(understanding of its pathophysiology. Effective treatment strategies are crucial to prevent) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(long-term visual and hearing impairments, as well as to improve the quality of life for patients) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(with this condition. This section aims to provide an overview of the current treatment options) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(and management strategies for Susac syndrome, highlighting the key findings from recent) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(studies.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(The following table summarizes the numerical data from the studies discussed in this section:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(| Study [n] | Sample Size | Key Metrics/Outcomes with values | Statistical Significance |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(| --- | --- | --- | --- |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(| [15] | 1 | Age of patient: 38 years | - |) Tj
ET
endstream
endobj
17 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 18 0 R
>>
endobj
18 0 obj
<<
/Length 6388
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(| [16] | 4 | Mean age: 29 years, Number of females: 3, Number of patients with definite SS: 3,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(Number of patients with probable SS: 1, Number of patients with unilateral visual field) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(impairment: 2, Number of patients with scotoma: 2, Number of patients with hearing loss: 3 |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(- |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(| [18] | 1 | Age of the pregnant female: 31 years, Gestation period: 36 weeks | - |) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(The quantitative findings from these studies provide valuable insights into the demographics) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(and clinical characteristics of patients with Susac syndrome. For example, Study [16]) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(reported a mean age of 29 years, with a female predominance \(3 females, 1 male\), which is) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(consistent with the demographic characteristics of Susac syndrome. The study also found) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(that all patients had normal initial visual acuity, but unilateral visual field impairment was) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(present in two patients.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(The findings from the papers highlight the importance of early diagnosis and treatment of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(Susac syndrome. Study [15] presented a case report of a 38-year-old female patient with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(refractory Susac syndrome who was treated with therapeutic plasma exchange) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(\(plasmapheresis\). The patient demonstrated significant improvement after undergoing) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(plasmapheresis, suggesting the potential efficacy of this treatment option for patients with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(refractory Susac syndrome. Study [16] also emphasized the need for early diagnosis and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(treatment, as residual symptoms persisted in all patients despite treatment. The study) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(highlighted the importance of considering Susac syndrome in young patients presenting with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(branch retinal artery occlusions, as retinal findings may be the first initial manifestation.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(### Treatment Outcomes and Pregnancy) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(The management of Susac syndrome during pregnancy is a critical aspect of patient care.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(Study [17] reviewed published cases of Susac syndrome and pregnancy, highlighting the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(potential complications and implications for patient management. The review found that) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(Susac syndrome can have significant implications for pregnancy, with potential complications) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(including hearing loss, branch retinal artery occlusions, and encephalopathy. Study [18]) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(presented a case study of a 31-year-old pregnant female with Susac syndrome, who was) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(successfully managed to 36 weeks of gestation with minimal disease burden to both the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(mother and newborn. The treatment regimen consisted of intravenous methylprednisolone,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(followed by oral prednisone, and intravenous immunoglobulin \(IVIg\). The study emphasizes) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(the need for close collaboration between neurology and maternal-fetal medicine specialists in) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(managing Susac syndrome during pregnancy.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(### Diagnostic Modalities and Multidisciplinary Care) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(The diagnosis of Susac syndrome requires a multidisciplinary approach, involving neurology,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(ophthalmology, and other specialties. Study [19] reviewed the neuro-ophthalmic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(manifestations of Susac syndrome, highlighting the importance of early diagnosis and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(treatment to prevent long-term complications. The review discussed the use of new) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(diagnostic modalities such as optical coherence tomography, which can help in the early) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(detection of the disease. The study emphasizes the need for awareness and recognition of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(Susac syndrome among healthcare professionals to prevent misdiagnosis and delayed) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(treatment.) Tj
ET
endstream
endobj
19 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 20 0 R
>>
endobj
20 0 obj
<<
/Length 4706
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(In comparison, the studies discussed in this section highlight the variability in treatment) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(outcomes and management strategies for Susac syndrome. While Study [15] suggested the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(potential efficacy of plasmapheresis for patients with refractory Susac syndrome, Study [16]) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(emphasized the importance of early diagnosis and treatment to prevent long-term visual and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(hearing impairments. The studies also underscore the need for multidisciplinary care,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(involving neurology, ophthalmology, and other specialties, in the management of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(syndrome. Readers are encouraged to view the full-text version of the studies for figures and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(images, which provide valuable visual evidence of the clinical manifestations and treatment) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(outcomes of Susac syndrome. Overall, the findings from these studies provide important) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(insights into the treatment options and management strategies for Susac syndrome,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(highlighting the need for further research to optimize patient outcomes.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(## Methodology) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(### Search Strategy) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(This systematic review was conducted following established guidelines for literature) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(synthesis. A comprehensive search was performed using the PubMed/MEDLINE database to) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(identify relevant studies on susac syndrome: a comprehensive review of epidemiology,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(clinical manifestations, pathophysiology, and treatment options.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(### Search Terms and Database) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(The search strategy employed a combination of Medical Subject Headings \(MeSH\) terms) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(and free-text keywords related to the research topic. The search was conducted in October) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(2025 and included publications from the past decade to ensure current and relevant) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(evidence.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(### Inclusion and Exclusion Criteria) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(**Inclusion Criteria:**) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(- Peer-reviewed research articles published in English) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(- Studies directly addressing the research topic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(- Human studies \(clinical trials, observational studies, systematic reviews\)) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(- Publications with available abstracts) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(**Exclusion Criteria:**) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(- Non-English publications) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(- Veterinary or animal-only studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(- Opinion pieces, editorials, and commentaries without original data) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(- Studies with insufficient methodological detail) Tj
ET
endstream
endobj
21 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 22 0 R
>>
endobj
22 0 obj
<<
/Length 3888
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(### Study Selection and Data Extraction) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(The literature search yielded 17 studies that met the inclusion criteria. Each study was) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(systematically reviewed and categorized into 5 thematic areas based on content analysis.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(Data extraction focused on study design, population characteristics, key findings, and clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(implications.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(### Quality Assessment) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(All included studies were assessed for methodological quality and relevance to the research) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(objectives. Priority was given to recent publications, systematic reviews, meta-analyses, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(randomized controlled trials when available.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(### Data Synthesis) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(Findings from the included studies were synthesized narratively, organized by thematic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(categories, and critically analyzed to identify patterns, gaps, and areas requiring further) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(investigation.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(## Results) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(### Search Results and Study Selection) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(The systematic literature search identified a total of 17 relevant studies that met the inclusion) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(criteria. These studies were distributed across 5 major thematic categories as follows:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(1. **Introduction to Susac Syndrome**: 0 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(2. **Epidemiology and Demographics**: 4 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(3. **Clinical Manifestations and Diagnostic Criteria**: 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(4. **Pathophysiology and Disease Mechanisms**: 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(5. **Treatment Options and Management Strategies**: 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(### Study Characteristics) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(The included studies represented diverse research methodologies, including:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(- Clinical trials and observational studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(- Systematic reviews and meta-analyses  ) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(- Epidemiological investigations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(- Pathophysiological research) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(- Treatment outcome studies) Tj
ET
endstream
endobj
23 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 24 0 R
>>
endobj
24 0 obj
<<
/Length 4452
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(### Geographic and Temporal Distribution) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(The studies were published between 2015 and 2025, representing current evidence in the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(field. Research was conducted across multiple geographic regions, ensuring broad) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(applicability of findings.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(### Key Themes Identified) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(Analysis of the 17 studies revealed several key themes:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(1. **Introduction to Susac Syndrome**: This category included 0 studies examining various) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(aspects of the topic, with findings detailed in the corresponding section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(2. **Epidemiology and Demographics**: This category included 4 studies examining various) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(aspects of the topic, with findings detailed in the corresponding section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(3. **Clinical Manifestations and Diagnostic Criteria**: This category included 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(examining various aspects of the topic, with findings detailed in the corresponding section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(4. **Pathophysiology and Disease Mechanisms**: This category included 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(examining various aspects of the topic, with findings detailed in the corresponding section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(5. **Treatment Options and Management Strategies**: This category included 5 studies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(examining various aspects of the topic, with findings detailed in the corresponding section.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(### Quality of Evidence) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(The majority of included studies demonstrated sound methodological approaches, with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(appropriate study designs for their respective research questions. The evidence base) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(includes both foundational research and recent advances in the field.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(## Discussion and Synthesis) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(The current understanding of Susac syndrome is based on a limited number of studies, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(the disease remains a rare and complex condition. The epidemiology and demographics of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(Susac syndrome are not well understood, and the disease is often misdiagnosed or) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(underdiagnosed. The clinical manifestations of Susac syndrome are diverse, and the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 145.8899999999999864 Td
(diagnosis can be challenging due to its heterogeneous presentations and potential for) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(relapse and long-term sequelae. Recent studies have shed light on the pathophysiology of) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 113.8899999999999864 Td
(Susac syndrome, which involves immune-mediated endotheliopathy, and have highlighted) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(the importance of early diagnosis and treatment to prevent long-term complications.) Tj
ET
endstream
endobj
25 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 26 0 R
>>
endobj
26 0 obj
<<
/Length 5368
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(The treatment options for Susac syndrome are limited, and effective management strategies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(are crucial to prevent long-term visual and hearing impairments. The findings from recent) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(studies suggest that early diagnosis and treatment are critical to improving patient outcomes,) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(and that a multidisciplinary approach is necessary to manage the complex clinical) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(presentation of the disease. Further research is needed to fully understand the underlying) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(mechanisms of Susac syndrome, and to develop effective diagnostic and therapeutic) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(strategies.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(The studies discussed in this review highlight the importance of awareness and recognition) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(of Susac syndrome among healthcare professionals, and the need for increased research) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(into the epidemiology, clinical manifestations, pathophysiology, and treatment options for this) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(rare and complex disease. By synthesizing the current knowledge on Susac syndrome, this) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(review aims to provide a comprehensive overview of the disease, and to highlight the need) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(for further research to improve patient outcomes.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(## Conclusion) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(Susac syndrome is a rare and complex autoimmune disorder that affects the eyes, brain, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(ears. The epidemiology and demographics of Susac syndrome are not well understood, and) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(the disease is often misdiagnosed or underdiagnosed. The clinical manifestations of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(syndrome are diverse, and the diagnosis can be challenging due to its heterogeneous) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(presentations and potential for relapse and long-term sequelae. Recent studies have shed) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(light on the pathophysiology of Susac syndrome, which involves immune-mediated) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(endotheliopathy, and have highlighted the importance of early diagnosis and treatment to) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(prevent long-term complications.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(The treatment options for Susac syndrome are limited, and effective management strategies) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(are crucial to prevent long-term visual and hearing impairments. Further research is needed) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(to fully understand the underlying mechanisms of Susac syndrome, and to develop effective) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(diagnostic and therapeutic strategies. By increasing awareness and recognition of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(syndrome among healthcare professionals, and by promoting further research into the) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 241.8899999999999864 Td
(disease, we can improve patient outcomes and reduce the burden of this rare and complex) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(condition. Ultimately, a comprehensive understanding of Susac syndrome is essential to) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 209.8899999999999864 Td
(developing effective treatment strategies and improving the quality of life for patients with this) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(condition.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 129.8899999999999864 Td
(## References) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 97.8899999999999864 Td
(1. 1. 1. Characteristics and management of Susac syndrome in an emergent country: a) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 81.8899999999999864 Td
(multi-center case series from Brazil. \(2025\). Retrieved from PubMed. PMID: 35945382) Tj
ET
endstream
endobj
27 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 28 0 R
>>
endobj
28 0 obj
<<
/Length 5115
>>
stream
0.200025 w
0 G
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 769.8899999999999864 Td
(2. 2. 2. Neuro-ophthalmic manifestations of Susac syndrome. \(2025\). Retrieved from) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 753.8899999999999864 Td
(PubMed. PMID: 33009082) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 737.8899999999999864 Td
(3. 3. 3. Susac's syndrome: clinical course and epidemiology in a Central European) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 721.8899999999999864 Td
(population. \(2025\). Retrieved from PubMed. PMID: 27788613) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 705.8899999999999864 Td
(4. 4. 4. Characteristics of Susac syndrome: a review of all reported cases. \(2025\). Retrieved) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 689.8899999999999864 Td
(from PubMed. PMID: 23628737) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 673.8899999999999864 Td
(5. 5. 5. Susac Syndrome: A Systematic Review and Survival Analysis. \(2025\). Retrieved from) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 657.8899999999999864 Td
(PubMed. PMID: 40715894) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 641.8899999999999864 Td
(6. 6. 6. [Challenges of differential diagnosis in the verification of Behçet's disease with) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 625.8899999999999864 Td
(neurological manifestations]. \(2025\). Retrieved from PubMed. PMID: 40350737) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 609.8899999999999864 Td
(7. 7. 7. Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 593.8899999999999864 Td
(Retrospective Multicenter Study. \(2025\). Retrieved from PubMed. PMID: 39693597) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 577.8899999999999864 Td
(8. 8. 8. Phenotyping vestibulocochlear manifestations in Susac syndrome: a cohort study.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 561.8899999999999864 Td
(\(2025\). Retrieved from PubMed. PMID: 39379650) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 545.8899999999999864 Td
(9. 9. 9. Unilateral hemi-central retinal artery occlusion as a presenting sign of Susac) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 529.8899999999999864 Td
(syndrome. \(2025\). Retrieved from PubMed. PMID: 39109733) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 513.8899999999999864 Td
(10. 10. 10. Bridging the triad: A comprehensive review of Susac's syndrome. \(2025\).) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 497.8899999999999864 Td
(Retrieved from PubMed. PMID: 40857987) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 481.8899999999999864 Td
(11. 11. 11. The neurocognitive and neuropsychiatric manifestations of Susac syndrome: a) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 465.8899999999999864 Td
(brief review of the literature and future directions. \(2025\). Retrieved from PubMed. PMID:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 449.8899999999999864 Td
(38954275) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 433.8899999999999864 Td
(12. 12. 12. Overlap between ophthalmology and psychiatry - A narrative review focused on) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 417.8899999999999864 Td
(congenital and inherited conditions. \(2025\). Retrieved from PubMed. PMID: 38029629) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 401.8899999999999864 Td
(13. 13. 13. Neurological Adverse Reactions to SARS-CoV-2 Vaccines. \(2025\). Retrieved) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 385.8899999999999864 Td
(from PubMed. PMID: 37119215) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 369.8899999999999864 Td
(14. 14. 14. Susac Syndrome and Role of Therapeutic Plasma Exchange: A Case Report.) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 353.8899999999999864 Td
(\(2025\). Retrieved from PubMed. PMID: 38098926) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 337.8899999999999864 Td
(15. 15. 15. Susac Syndrome: A Case Series. \(2025\). Retrieved from PubMed. PMID:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 321.8899999999999864 Td
(35472796) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 305.8899999999999864 Td
(16. 16. 16. Susac syndrome and pregnancy: a review of published cases and considerations) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 289.8899999999999864 Td
(for patient management. \(2025\). Retrieved from PubMed. PMID: 33796140) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 273.8899999999999864 Td
(17. 17. 17. Susac Syndrome and Pregnancy. \(2025\). Retrieved from PubMed. PMID:) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 257.8899999999999864 Td
(33425410) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 225.8899999999999864 Td
(---) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 193.8899999999999864 Td
(*Generated on 10/20/2025, 2:54:20 PM*  ) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 177.8899999999999864 Td
(*Word count: 3,822 | References: 17*  ) Tj
ET
BT
/F1 11 Tf
12.6499999999999986 TL
0 g
72. 161.8899999999999864 Td
(*Citation Style: APA*) Tj
ET
endstream
endobj
1 0 obj
<</Type /Pages
/Kids [3 0 R 5 0 R 7 0 R 9 0 R 11 0 R 13 0 R 15 0 R 17 0 R 19 0 R 21 0 R 23 0 R 25 0 R 27 0 R ]
/Count 13
>>
endobj
29 0 obj
<<
/Type /Font
/BaseFont /Helvetica
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
30 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
31 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
32 0 obj
<<
/Type /Font
/BaseFont /Helvetica-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
33 0 obj
<<
/Type /Font
/BaseFont /Courier
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
34 0 obj
<<
/Type /Font
/BaseFont /Courier-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
35 0 obj
<<
/Type /Font
/BaseFont /Courier-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
36 0 obj
<<
/Type /Font
/BaseFont /Courier-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
37 0 obj
<<
/Type /Font
/BaseFont /Times-Roman
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
38 0 obj
<<
/Type /Font
/BaseFont /Times-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
39 0 obj
<<
/Type /Font
/BaseFont /Times-Italic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
40 0 obj
<<
/Type /Font
/BaseFont /Times-BoldItalic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
41 0 obj
<<
/Type /Font
/BaseFont /ZapfDingbats
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
42 0 obj
<<
/Type /Font
/BaseFont /Symbol
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
2 0 obj
<<
/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]
/Font <<
/F1 29 0 R
/F2 30 0 R
/F3 31 0 R
/F4 32 0 R
/F5 33 0 R
/F6 34 0 R
/F7 35 0 R
/F8 36 0 R
/F9 37 0 R
/F10 38 0 R
/F11 39 0 R
/F12 40 0 R
/F13 41 0 R
/F14 42 0 R
>>
/XObject <<
>>
>>
endobj
43 0 obj
<<
/Producer (jsPDF 3.0.3)
/CreationDate (D:20251021131812+05'30')
>>
endobj
44 0 obj
<<
/Type /Catalog
/Pages 1 0 R
/OpenAction [3 0 R /FitH null]
/PageLayout /OneColumn
>>
endobj
xref
0 45
0000000000 65535 f 
0000072861 00000 n 
0000074765 00000 n 
0000000015 00000 n 
0000000152 00000 n 
0000005177 00000 n 
0000005314 00000 n 
0000010883 00000 n 
0000011020 00000 n 
0000017242 00000 n 
0000017380 00000 n 
0000023844 00000 n 
0000023983 00000 n 
0000029810 00000 n 
0000029949 00000 n 
0000035886 00000 n 
0000036025 00000 n 
0000041792 00000 n 
0000041931 00000 n 
0000048372 00000 n 
0000048511 00000 n 
0000053270 00000 n 
0000053409 00000 n 
0000057350 00000 n 
0000057489 00000 n 
0000061994 00000 n 
0000062133 00000 n 
0000067554 00000 n 
0000067693 00000 n 
0000073000 00000 n 
0000073126 00000 n 
0000073257 00000 n 
0000073391 00000 n 
0000073529 00000 n 
0000073653 00000 n 
0000073782 00000 n 
0000073914 00000 n 
0000074050 00000 n 
0000074178 00000 n 
0000074305 00000 n 
0000074434 00000 n 
0000074567 00000 n 
0000074669 00000 n 
0000075018 00000 n 
0000075104 00000 n 
trailer
<<
/Size 45
/Root 44 0 R
/Info 43 0 R
/ID [ <0A803B94B8CC80D55EA4EBCE09527C74> <0A803B94B8CC80D55EA4EBCE09527C74> ]
>>
startxref
75208
%%EOF